Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.
A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.
A new review of antipsychotic trials conducted over the last 24 years finds that the placebo response rate is steadily increasing, and drug response is decreasing.
New research counters the long-held assumption that a longer duration of untreated psychosis is associated with worse outcomes.
A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.
A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.
New study examines the experiences of people utilizing an exercise program following a first-episode psychosis.
The approval of the digital antipsychotic may open the door for more pharmaceutical company profits without evidence of benefits to patients.
People who take anticholinergic drugs, such as antidepressants and antipsychotics, are at a 50% higher risk of dementia.
A new meta-review examines the experiences of antipsychotic drugs use among people diagnosed with a psychotic disorder.
A new study has found that of 10 people who were fully recovered from their first episode of schizophrenia (FES), those not taking antipsychotics did better in terms of cognitive, social, and role functioning—and reached full recovery more quickly.
A new study has found that children and adolescents taking a high dose of antipsychotics are almost twice as likely to die of any cause than children on other types of medications.
Researchers reveal the limitations and misleading interpretations of two recent studies that claim to demonstrate that long-term antipsychotic use leads to better outcomes.
Researchers discuss the evidence that antipsychotic medications may cause brain atrophy in children, whose brains are still developing.
A new analysis of antipsychotic treatment of schizophrenia (published in Schizophrenia Bulletin) has found that two-thirds of patients treated this way do not experience symptom remission.
A systematic review of the limited research available on the long-term effects of antipsychotics finds fewer symptoms in those off of the drugs.
Researchers point to the risks of using antipsychotics with youth and caution against the practice.
Study finds that reduced cortical thickness and brain surface area associated with 'schizophrenia' may result from antipsychotic drug use.
With increasing evidence that psychiatric drugs do more harm than good over the long term, the field of psychiatry often seems focused on sifting through the mounds of research data it has collected, eager to at last sit up and cry, here’s a shiny speck of gold! Our drugs do work! One recently published study on withdrawal of antipsychotics tells of long-term benefits. A second tells of long-term harm. Which one is convincing?
A new study offers radical solutions for improving the cardiovascular health of people with mental health diagnoses: reducing antipsychotic prescriptions..
A new study, published in the Journal of Clinical Psychiatry, investigates the effects of anticholinergic medications, such as antidepressants and antipsychotics, on cognition in older adults diagnosed with schizophrenia.
The researchers found that while antipsychotic drugs may be slightly more effective than alternative antidepressants, they come with a much higher side effect burden.
One-third of adults with an intellectual or developmental disability are dispensed antipsychotics, despite having no existing psychiatric diagnosis.
Large cohort study demonstrates that those with an intellectual disability are at an increased risk for movement disorder side effects of antipsychotics.
20-year follow-up study finds that after four years, patients not prescribed antipsychotics have significantly better work functioning.
12Page 1 of 2